2024
Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting.
Santucci M, Ansari M, Nikayin S, Radhakrishnan R, Rhee T, Wilkinson S. Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting. The Journal Of Clinical Psychiatry 2024, 85 PMID: 39361411, DOI: 10.4088/jcp.24m15376.Peer-Reviewed Original ResearchConceptsBipolar depressionAcute seriesRisk of affective switchDiagnosis of bipolar depressionRefractory bipolar depressionAcute phaseMADRS scoreAffective switchIntranasal esketamineManic episodesBipolar disorderCohort of patientsAttending psychiatristsSource of morbidityEsketamineSample of patientsIV ketamineMaintenance treatmentDepressionClinical responseHeightened riskClinical outcomesMania/hypomaniaKetamineKetamine/esketamine
2023
Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments
Krystal J, Kaye A, Jefferson S, Girgenti M, Wilkinson S, Sanacora G, Esterlis I. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2305772120. PMID: 38011560, PMCID: PMC10710048, DOI: 10.1073/pnas.2305772120.Peer-Reviewed Original ResearchKetamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
Anand A, Mathew S, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Collins K, Costi S, Iqbal S, Jha M, Krishnan K, Malone D, Nikayin S, Nissen S, Ostroff R, Reti I, Wilkinson S, Wolski K, Hu B. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal Of Medicine 2023, 388: 2315-2325. PMID: 37224232, DOI: 10.1056/nejmoa2302399.Peer-Reviewed Original ResearchConceptsTreatment-resistant major depressionPatient-reported qualityElectroconvulsive therapyMajor depressionECT groupKetamine groupTreatment phaseMusculoskeletal adverse effectsSubanesthetic intravenous ketamineWeeks of treatmentInitial treatment phaseIntravenous ketamineSecondary outcomesPrimary outcomeNoninferiority marginTrial groupECT clinicsNoninferiority trialPatientsComparative effectivenessKetamineClinical sitesAdverse effectsDepressionThree timesThe Role of Psychotherapy in the Management of Treatment-Resistant Depression
Rogan T, Wilkinson S. The Role of Psychotherapy in the Management of Treatment-Resistant Depression. Psychiatric Clinics Of North America 2023, 46: 349-358. PMID: 37149349, DOI: 10.1016/j.psc.2023.02.006.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionRole of psychotherapySomatic therapiesLong-term outcomesPositive therapeutic benefitsPsychotherapy modalitiesRandomized trialsMood disordersTherapeutic benefitNeural plasticityTherapyMore trialsForms of psychotherapyTrialsDepressionLess evidenceModalitiesPsychotherapy approachesPsychotherapyPotential combinations
2020
Ketamine, Esketamine, and A New Generation of Antidepressants
Wilkinson S, Kitay B. Ketamine, Esketamine, and A New Generation of Antidepressants. Psychiatric Annals 2020, 50: 54-61. DOI: 10.3928/00485713-20200113-02.Peer-Reviewed Original ResearchTreatment-resistant depressionGamma-aminobutyric acid (GABA) neurotransmitter systemRapid-acting antidepressantsSAGE-217Clinical evidenceAntidepressant propertiesPostpartum depressionNeurotransmitter systemsLate-stage developmentClinical practiceDrug AdministrationUS FoodFDA approvalKetamineEsketamineAntidepressantsRegulatory approvalDepressionApprovalAllopregnanoloneBrexanoloneS-enantiomerRisk evaluationTherapyAdministration